Repare Therapeutics Reacquires Global Rights to Camonsertib

Repare Therapeutics to Regain Global Rights to Camonsertib Following Collaboration Termination with Roche”

Repare Therapeutics Inc. (Nasdaq: RPTX), a prominent clinical-stage precision oncology company, has announced its intention to reclaim global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase). This move follows the termination of its collaboration agreement with Roche.

Roche informed Repare of its decision to terminate the worldwide license and collaboration agreement for camonsertib’s development and commercialization, effective May 7, 2024. This decision came after a review of Roche’s pipeline and evolving external factors. With this termination, Repare now regains full control of all rights for camonsertib, a promising best-in-class ATR inhibitor.

Lloyd M. Segal, President and Chief Executive Officer of Repare, expressed the value of camonsertib as a precision oncology medicine with clinical proof-of-concept in multiple tumor types and genotypes, both as monotherapy and in combination. He stated Repare’s commitment to continuing the progress of this therapy, despite the disappointment of ending the collaboration with Roche. Repare’s deep clinical pipeline now includes four wholly-owned synthetic lethal therapies.

Camonsertib is currently being evaluated in Repare’s ongoing Phase 1 MYTHIC trial, investigating its combination with lunresertib, a first-in-class, oral small molecule inhibitor of PKMYT1, in patients with molecularly selected, advanced solid tumors. Initial data presented by Repare in October 2023 showed promising clinical benefit across multiple tumor types and genotypes with this combination therapy. Additional data from the expansion cohorts of this trial are expected to be reported in the second half of 2024.

Repare has fulfilled all obligations under the Roche agreement to date and received a $40 million milestone payment. The company anticipates that its existing financial resources will be adequate to fund planned operations into mid-2026.

Repare Therapeutics’ SNIPRx® platform, a genome-wide CRISPR-based screening approach, plays a crucial role in identifying synthetic lethal gene pairs and corresponding patients likely to benefit from its therapies. This platform enables the development of precision therapeutics to selectively target tumors with specific genomic alterations.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company leveraging its proprietary synthetic lethality approach for the discovery and development of novel cancer therapeutics. Utilizing its genome-wide, CRISPR-enabled SNIPRx® platform, Repare focuses on developing highly targeted therapies for genomic instability, including DNA damage repair. The company’s pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development, and camonsertib (RP-3500), a potential leading ATR inhibitor in Phase 1/2 clinical development, among others.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter